FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136964832> ?p ?o ?g. }

• W3136964832 endingPage "1467" @default.
• W3136964832 startingPage "1458" @default.
• W3136964832 abstract "The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with endocrine therapy and ribociclib (RIB) is currently unknown. We evaluated the association of intrinsic subtypes with progression-free survival (PFS) in the MONALEESA trials.A retrospective and exploratory PAM50-based analysis of tumor samples from the phase III MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials was undertaken. The prognostic relationship of PAM50-based subtypes with PFS and risk of disease progression by subtype and treatment were evaluated using a multivariable Cox proportional hazards model, adjusting for age, prior chemotherapy, performance status, visceral disease, bone-only metastases, histological grade, number of metastatic sites, prior endocrine therapy, and de novo metastatic disease.Overall, 1,160 tumors from the RIB (n = 672) and placebo (n = 488) cohorts were robustly profiled. Subtype distribution was luminal A (LumA), 46.7%; luminal B (LumB), 24.0%; normal-like, 14.0%; HER2-enriched (HER2E), 12.7%; and basal-like, 2.6% and was generally consistent across treatment arms and trials. The associations between subtypes and PFS were statistically significant in both arms (P < .001). The risks of disease progression for LumB, HER2E, and basal-like subtypes were 1.44, 2.31, and 3.96 times higher compared with those for LumA, respectively. All subtypes except basal-like demonstrated significant PFS benefit with RIB. HER2E (hazard ratio [HR], 0.39; P < .0001), LumB (HR, 0.52; P < .0001), LumA (HR, 0.63; P = .0007), and normal-like (HR, 0.47; P = .0005) subtypes derived benefit from RIB. Patients with basal-like subtype (n = 30) did not derive benefit from RIB (HR, 1.15; P = .77).In this retrospective exploratory analysis of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer, each intrinsic subtype exhibited a consistent PFS benefit with RIB, except for basal-like." @default.
• W3136964832 created "2021-03-29" @default.
• W3136964832 creator A5005092860 @default.
• W3136964832 creator A5014379154 @default.
• W3136964832 creator A5019569585 @default.
• W3136964832 creator A5034763642 @default.
• W3136964832 creator A5041227452 @default.
• W3136964832 creator A5047554462 @default.
• W3136964832 creator A5051949967 @default.
• W3136964832 creator A5061522111 @default.
• W3136964832 creator A5067617700 @default.
• W3136964832 creator A5077175788 @default.
• W3136964832 creator A5085882730 @default.
• W3136964832 creator A5089513581 @default.
• W3136964832 date "2021-05-01" @default.
• W3136964832 modified "2023-10-12" @default.
• W3136964832 title "Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies" @default.
• W3136964832 cites W2000881757 @default.
• W3136964832 cites W2062071674 @default.
• W3136964832 cites W2132619562 @default.
• W3136964832 cites W2135696440 @default.
• W3136964832 cites W2141414987 @default.
• W3136964832 cites W2144442992 @default.
• W3136964832 cites W2153206149 @default.
• W3136964832 cites W2156527837 @default.
• W3136964832 cites W2166311434 @default.
• W3136964832 cites W2414214572 @default.
• W3136964832 cites W2528767298 @default.
• W3136964832 cites W2591481727 @default.
• W3136964832 cites W2591810315 @default.
• W3136964832 cites W2792709310 @default.
• W3136964832 cites W2802776309 @default.
• W3136964832 cites W2804105316 @default.
• W3136964832 cites W2805575723 @default.
• W3136964832 cites W2897422388 @default.
• W3136964832 cites W2912143634 @default.
• W3136964832 cites W2917464640 @default.
• W3136964832 cites W2925017918 @default.
• W3136964832 cites W2948069739 @default.
• W3136964832 cites W2969909201 @default.
• W3136964832 cites W2974027076 @default.
• W3136964832 cites W3010635529 @default.
• W3136964832 cites W3133509869 @default.
• W3136964832 doi "https://doi.org/10.1200/jco.20.02977" @default.
• W3136964832 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8196091" @default.
• W3136964832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33769862" @default.
• W3136964832 hasPublicationYear "2021" @default.
• W3136964832 type Work @default.
• W3136964832 sameAs 3136964832 @default.
• W3136964832 citedByCount "61" @default.
• W3136964832 countsByYear W31369648322021 @default.
• W3136964832 countsByYear W31369648322022 @default.
• W3136964832 countsByYear W31369648322023 @default.
• W3136964832 crossrefType "journal-article" @default.
• W3136964832 hasAuthorship W3136964832A5005092860 @default.
• W3136964832 hasAuthorship W3136964832A5014379154 @default.
• W3136964832 hasAuthorship W3136964832A5019569585 @default.
• W3136964832 hasAuthorship W3136964832A5034763642 @default.
• W3136964832 hasAuthorship W3136964832A5041227452 @default.
• W3136964832 hasAuthorship W3136964832A5047554462 @default.
• W3136964832 hasAuthorship W3136964832A5051949967 @default.
• W3136964832 hasAuthorship W3136964832A5061522111 @default.
• W3136964832 hasAuthorship W3136964832A5067617700 @default.
• W3136964832 hasAuthorship W3136964832A5077175788 @default.
• W3136964832 hasAuthorship W3136964832A5085882730 @default.
• W3136964832 hasAuthorship W3136964832A5089513581 @default.
• W3136964832 hasBestOaLocation W31369648321 @default.
• W3136964832 hasConcept C121608353 @default.
• W3136964832 hasConcept C126322002 @default.
• W3136964832 hasConcept C142724271 @default.
• W3136964832 hasConcept C143998085 @default.
• W3136964832 hasConcept C204787440 @default.
• W3136964832 hasConcept C207103383 @default.
• W3136964832 hasConcept C23589133 @default.
• W3136964832 hasConcept C27081682 @default.
• W3136964832 hasConcept C2776694085 @default.
• W3136964832 hasConcept C2778024521 @default.
• W3136964832 hasConcept C2779134260 @default.
• W3136964832 hasConcept C2779306644 @default.
• W3136964832 hasConcept C2780739268 @default.
• W3136964832 hasConcept C44249647 @default.
• W3136964832 hasConcept C50382708 @default.
• W3136964832 hasConcept C530470458 @default.
• W3136964832 hasConcept C71924100 @default.
• W3136964832 hasConceptScore W3136964832C121608353 @default.
• W3136964832 hasConceptScore W3136964832C126322002 @default.
• W3136964832 hasConceptScore W3136964832C142724271 @default.
• W3136964832 hasConceptScore W3136964832C143998085 @default.
• W3136964832 hasConceptScore W3136964832C204787440 @default.
• W3136964832 hasConceptScore W3136964832C207103383 @default.
• W3136964832 hasConceptScore W3136964832C23589133 @default.
• W3136964832 hasConceptScore W3136964832C27081682 @default.
• W3136964832 hasConceptScore W3136964832C2776694085 @default.
• W3136964832 hasConceptScore W3136964832C2778024521 @default.
• W3136964832 hasConceptScore W3136964832C2779134260 @default.
• W3136964832 hasConceptScore W3136964832C2779306644 @default.
• W3136964832 hasConceptScore W3136964832C2780739268 @default.
• W3136964832 hasConceptScore W3136964832C44249647 @default.

• next